KBPH Kyto Technology and Life Science Inc (CE)

Kyto Biopharma Inc. (OTCBB: KBPH), is a biotechnology company focused on developing monoclonal antibody and oligonucleotide targeting therapeutics based on a proprietary vitamin B12 platform for the treatment of various forms of cancer.

Vitamin B12 regulates one of two major cellular pathways for the production of folates, the progenitor for the synthesis of DNA. Cancer cells require increased levels of vitamin B12 for proliferation than do normal cells and in turn over-express the receptor for the uptake of vitamin B12. Using its technology, Kyto is targeting the over-expression of the vitamin B12 receptor in the treatment of various forms of cancer. The primary approach developed by Kyto is directed at selective targeting of the vitamin B12 receptor in cancer cells by monoclonal antibodies. This approach intends to minimize many of the potential complications arising from current chemotherapy treatments such as acute systemic toxicity. The Kyto technology is intended to exploit over-expression of vitamin B12 receptors in cancer cells by coupling toxins to targeting the vitamin B12 receptor monoclonal antibodies.

Kyto has previously announced that through its research and co operation agreement with SUNY, it has been able to identify and purify the protein and gene encoding receptor for the cellular uptake of vitamin B12. This seminal discovery was the subject of an article entitled “The protein and the gene encoding the receptor for the cellular uptake of transcobalamin - bound cobalamin” and which was published in the scientific journal “Blood” in January 2009, by Dr. Edward Quadros and his colleagues at SUNY.

Kyto’s Research and Development strategy is to develop monoclonal antibodies to the vitamin B12 receptor as specific delivery vehicles for cytotoxic payloads. In addition Kyto is identifying select malignancies that are most sensitive to the vitamin B12 receptor antibody-payload conjugates. Kyto has recently achieved a critical milestone in that respect.

Kyto has been successful in developing a specific murine monoclonal antibody to the transcobalamin receptor. The antibody identified as mAbTCR23, has been demonstrated to be highly effective in targeting cancer cells and in inhibiting cell proliferation in a number of cell lines including solid tumors and lymphnoid malignancies. The conjugation of the mAbTCR23 antibody to saporin, a highly effective intercellular cytotoxic agent, did not affect the biological activity of the antibody.

The mAbTCR23 –Saporin Conjugate studies demonstrate that i. A monoclonal antibody to the Transcobalamin receptor is an effective reagent for targeting cancer cells. ii. The effective dose of the antibody-saporin conjugate is in the nanomolar range, a concentration easily achievable in humans. iii. The target for toxin delivery appears to be specific for rapidly dividing cells and therefore would provide selective targeting to rapidly proliferating cancer cells. iv. The low dose of the antibody-toxin conjugate required is anticipated to limit systemic toxicity in humans.

“The development of an effective high affinity antibody-toxin conjugate to the transcobalamin receptor is a significant milestone for Kyto and shows definitive evidence to the validity of the Kyto technology”, stated Dr. Uri Sagman, one of the founders and a director of Kyto.

Kyto is proceeding with plans for achieving the next critical milestones and is advancing with a program for humanization of the mAbTCR23 antibody. Kyto estimates that a humanized version of mAbTCR23 will be completed in late 2010. “Over the next few months, we shall concentrate on the humanization of the antibody while we start looking for a partner who can participate with Kyto to advance the platform through Phase I testing. As we see more evidence of renewed interest in the pharmaceutical sector at the pre-clinical level, we are encouraged in our belief that our focus will be rewarded” said Georges Benarroch, President, one of the founders of Kyto, President of Credifinance Capital, and Kyto’s largest shareholder.

About Kyto Biopharma Inc.

Kyto Biopharma Inc. is a Florida based biotechnology company operating from Toronto, Canada, developing monoclonal antibody therapies for the treatment of various forms of cancer. The Kyto research and development program is conducted under the scientific leadership of Dr. Edward Quadros of the State University of New York (SUNY Brooklyn), and Dr. Michael Rosenblum of the MD Anderson Cancer Centre (Houston). Kyto owns a very strong portfolio of intellectual property which includes the newly discovered TCblR gene. The Company intends to develop its Vitamin B12 receptor based technology and find a suitable partner to assist with the development and commercialization of a marketable cancer therapeutic. Vitamin B12 regulates one of two major cellular pathways for the production of Folates, the cell’s primary source of carbon and the progenitor for the synthesis of DNA. The newly isolated vitamin B12 receptor is over expressed in a host of various forms of cancer cells and serves as a viable target for development of therapeutic monoclonal antibodies.

Safe Harbor

This release contains forward looking statements that reflect, among other things, management’s current expectations, plans and strategies, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Many of these risks are beyond our ability to control or predict. Please see “Risk Factors” in the Company’s public filings with the Securities and Exchange Commission for a discussion of such risks, including the Company’s need for additional funds, the Company’s dependence on a limited number of therapeutic compounds , the stage of the products the Company is developing, uncertainties relating to clinical trials and regulatory reviews, competition and dependence on collaborative partners, the company’s ability to avoid infringement of the patent rights of others, and the company’s ability to obtain adequate patent protection and to enforce these rights. Because of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the date they are released. Kyto Biopharma does not undertake any obligation to update or review any such forward-looking information, whether as a result of new information, future events or otherwise.

Kyto Technology and Life... (CE) (USOTC:KBPH)
과거 데이터 주식 차트
부터 2월(2) 2025 으로 3월(3) 2025

Kyto Technology and Life... (CE) (USOTC:KBPH)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025